flow trial semaglutide kidney outcomes nejm 2024 hazard ratio Semaglutides Are Poised to Remake Chronic Kidney Disease Care Get With the FLOW! in:

If you take an SGLT2 inhibitor alongside tirzepatide, you will almost certainly notice more frequent urination, and it is the SGLT2 inhibitor doing most of the work

This is huge because brown fat is metabolically active fat and it causes you to burn a lot more calories than you normally would, leading to a leaner body

Fair use statement The data and findings presented in this article are available for noncommercial use

A better understanding of dose-response relationships is needed to optimize therapy

If your progress has stalled, a weight-loss plateau on semaglutide may be worth understanding before changing your plan